Overview

SPI-1005 Treatment in Severe COVID-19 Patients

Status:
Enrolling by invitation

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19 disease.

Phase:

Phase 2

Details

Lead Sponsor:

Sound Pharmaceuticals, Incorporated

Treatments:

Ebselen